Status:
UNKNOWN
Morpho-functional Cardiac Modifications in Treated Mutated Transthyretin Cardiac Amyloidosis
Lead Sponsor:
University of Messina
Collaborating Sponsors:
Campisi Mariapaola
Conditions:
Cardiac Amyloidosis
Eligibility:
All Genders
18-90 years
Brief Summary
Cardiac Amyloidosis (CA) is characterized by a long subclinical phase characterized by deposition of amyloid fibrils in atria, valves and walls of ventricles. Longitudinal dysfunction of the left vent...
Detailed Description
Transthoracic echocardiographic images are recorded in the available ultrasound units (Vivid 7 and Vivid 9, GE Ultrasound, Horten, Norways and MyLab - Esaote, Genoa, Italy). The diameters and the wall...
Eligibility Criteria
Inclusion
- presence of data obtained from historical records of patients who retrospectively met the prescriptive (neurological) criteria and received the prescription of the drugs in question (RNA interferences) having
- Cardiological evaluation (examination ECG, echocardiography) at the time of prescription
- Cardiological evaluation (examination ECG, echocardiography) evaluated six months after therapy,
- Cardiological evaluation (examination ECG, echocardiography) evaluated 12-18 months after therapy,
Exclusion
- it wasn't possible to putatively confirm the reasonable shipment of the innovative therapy prescribed
- it wasn't possible to putatively confirm the reasonable shipment of conventional therapy prescribed (background therapy)
Key Trial Info
Start Date :
May 20 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2020
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT04387344
Start Date
May 20 2020
End Date
December 30 2020
Last Update
May 13 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Careggi Hospital
Florence, Italy
2
Fondazione Policlinico Universitario A. Gemelli IRCCS.
Roma, Italy